Financial toxicity in clinical care today: a “menu without prices”
Authors: Sanchia Aranda and David Currow
Published online: 12 December 2016
Cancer has an impact on patients and their families in a myriad of ways. As Koczwara and colleagues point out in their letter, this is not just related to the direct costs of clinical care, which was the main focus of our article,1 but may impact the treatment decisions or alter the life course in many ways.
Cancer interrupts people’s lives. To date, there has been too little emphasis on the long term effects of cancer, even after successful definitive treatment. Many people give account of prolonged periods of time when they are unable to work, or are unable to work at the level at which they did before. Too little attention has been paid to the physical rehabilitation of patients, especially if their cancer treatment is otherwise considered a success.
Cancer and its treatments entail a number of challenges to the physical and emotional wellbeing. To optimise health outcomes, it is crucial to ensure adequate support for patients and their families from the time that cancer is recognised until they have returned to the best level of function they will be able to achieve, and this may be months or even years after treatment starts.2
It is required to have a greater understanding of the broader financial burden of cancer, its treatment and impact on work, to better establish services to assist with rehabilitation, which may critically help reduce the financial factors contributing to poorer outcomes for people of lower financial capacity, and to the wider impact a cancer diagnosis may have for the family.
Competing interests
References
- Currow D, Aranda S. Financial toxicity in clinical care today: a “menu without prices”. Med J Aust 2016; 204: 397.
- de Boer AG, Taskila TK, Tamminga SJ, et al. Interventions to enhance return-to-work for cancer patients. Cochrane Database Syst Rev 2015; (9): CD007569.
Challenges and Opportunities for Strong and Dynamic Foundations in the Australian Cancer Plan
Ashley M. Hopkins, Andrew Rowland, Natansh D. Modi, Ceara Rickard, Mark Haseloff, Norma B. Bulamu, Imogen Ramsey, Niranjan Bidargaddi, Ganessan Kichenadasse, Michael J. Sorich, Kalinda E. Griffiths, Aideen McInerney-Leo, David M. Roder, Raymond J. Chan
Opportunities and Challenges to Achieving the Australian Cancer Plan Goal of World Class Health Systems for Optimal Cancer Care
Carolyn Ee, Ria Joseph, Elise Button, Stacey George, Makala Castelli, David Currow, Prue Cormie, Olivia Farrer, Michael Jefford, Nicolas H. Hart, Chad Y. Han, Deidre D. Morgan, Michael P. Osborn, Candice Oster, Joel Rhee, Anna Ugalde, Eric Yeung, Catherine Paterson
Maximising Cancer Prevention and Early Detection in the Australian Cancer Plan: Where Are We Now and What Should Come Next?
Erin L. Symonds, Billie Bonevski, Richard Edwards, Nathan J. Harrison, Sana Ishaque, Nicole M. Rankin, Sibel Saya, Renee J. Smith, Carolyn Ee
An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres
Sarah Childs, David Ma, Anthony Rodrigues, Jennifer Massey, Rasha Cosman, Venessa Chin, Laila Girgis, James Lynam, Peter Lau, Barbara Withers, Anthony M. Joshua, Ben Tran, Jayesh Desai, Simon J. Harrison, John Moore, Jia Liu
Peritoneal Tuberculosis and Chronic Myeloid Leukaemia: A Case of Hickam's Dictum
Zayn Al-Timimi, Gem Chew, Martin Browne, Christiaan Mostert
From Ambition to Action: Closing Policy, Equity and Implementation Gaps in the Australian Cancer Plan's ‘Enhanced Consumer Experience’
Carla Thamm, Elise Button, Oluwaseyifunmi A. Agbejule, Reegan Knowles, Karen van Gorp, Mark B. Pinkham, Meinir Krishnasamy, Alexandra L. McCarthy, Raymond J. Chan